RYTM — Rhythm Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.06bn
- $5.83bn
- $189.76m
Rhythm rises as drug helps patients with rare form of obesity in small trial
Rhythm's drug helps patients with brain damage-related obesity in small study (updated)
Rhythm's experimental drug to treat a form of obesity meets main goal in study
Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug
U.S. STOCKS ON THE MOVE-Ionis Pharmaceuticals, Saia, Viatris
U.S. STOCKS ON THE MOVE-Janover, AMC Entertainment, U.S. Steel
U.S. STOCKS ON THE MOVE-Rhythm Pharma, One Gas, Robinhood Markets
Rhythm Pharma rises as rare obesity disorder drug meets main goal of late-stage study
Brief: Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial (updated)
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial
Brief: Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Brief: Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan
Rhythm Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Rhythm Pharmaceuticals Imcivree Net Revenue FY24 Expected To Be About $130 Million
Brief: Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old
Rhythm Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Rhythm Pharmaceuticals Q3 Net Income USD -43.641 Million